LXRα deficiency promotes hepatic tumor development in nonalcoholic fatty liver disease and alters Akt/Gsk3β/β-catenin signaling
Biochemical and Biophysical Research Communications · 2026
DOI: 10.1016/j.bbrc.2026.154647 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2026. Verfasst von Seungwoo Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nonclinical Resources Research Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju-si, 28159,…. Hauptthemen laut MEDLINE: Liver X Receptors, Non-alcoholic Fatty Liver Disease, Glycogen Synthase Kinase 3 beta, beta Catenin. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Korea Ministry of Food and Drug Safety.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide, with nonalcoholic fatty liver disease (NAFLD) emerging as an increasingly important risk factor. Liver X receptor alpha (LXRα) regulates hepatic lipid and cholesterol homeostasis, but its role in NAFLD-associated hepatic tumor development remains unclear. We examined hepatic LXRα expression in transcriptomic datasets and human liver tissue from cirrhosis and HCC to assess its association with chronic liver disease and hepatic malignancy. To model NAFLD-associated hepatic tumor development, wild-type (WT) and Lxrα knockout (KO) mice were fed a choline-deficient, l-amino acid-defined, high-fat diet (CDAHFD) for 26 weeks. Hepatic LXRα expression was reduced in human cirrhosis and HCC. Relative to WT mice, CDAHFD-fed Lxrα KO mice developed more hepatic nodules, larger maximum nodules, hepatocellular adenomas, and increased GPC3 expression. LXRα deficiency also enhanced hepatocyte proliferation and altered Akt/Gsk3β/β-catenin signaling, with increased expression of proliferation markers and nuclear accumulation of β-catenin. In addition, LXRα deficiency exacerbated hepatic fibrosis, inflammation, oxidative damage, and neutrophil infiltration but did not significantly alter hepatic steatosis or hepatic and serum lipid levels. These findings implicate LXRα as a potential regulator of NAFLD-associated hepatic tumor development and clarify the mechanisms underlying this process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nonclinical Resources Research Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju-si, 28159, Republic of Korea.
- Nonclinical Resources Research Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju-si, 28159, Republic of Korea. Electronic address: rheedalee@korea.kr.
Förderung
- Korea Ministry of Food and Drug Safety
Zitieren
APA
Lee, S., Na, H. J., Park, J. K., Kim, W. S., Seok, J., & Lee, R. (2026). LXRα deficiency promotes hepatic tumor development in nonalcoholic fatty liver disease and alters Akt/Gsk3β/β-catenin signaling. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2026.154647
Vancouver
Lee S, Na HJ, Park JK, Kim WS, Seok J, Lee R. LXRα deficiency promotes hepatic tumor development in nonalcoholic fatty liver disease and alters Akt/Gsk3β/β-catenin signaling. Biochemical and Biophysical Research Communications. 2026. doi:10.1016/j.bbrc.2026.154647
BibTeX
@article{Lee2026,
author = {Lee, Seungwoo and Na, Hye-Jee and Park, Ju Kyeong and Kim, Won Seob and Seok, Jihyeon and Lee, Rheeda},
title = {LXRα deficiency promotes hepatic tumor development in nonalcoholic fatty liver disease and alters Akt/Gsk3β/β-catenin signaling},
journal = {Biochemical and Biophysical Research Communications},
year = {2026},
doi = {10.1016/j.bbrc.2026.154647}
}
EUVIMED